Core Viewpoint - The approval of Chloride Dihydropyridine Injection by the National Medical Products Administration of China represents a significant advancement for the company in the cardiovascular treatment sector, addressing an unmet clinical need for emergency hypertension medications [1] Company Summary - The product is a dihydropyridine calcium channel blocker, classified as a rapid-acting intravenous antihypertensive drug, suitable for patients who cannot take oral medications or have poor expected responses to oral treatments [1] - The injection comes in two formulations: 50ml with 25mg and 100ml with 50mg [1] - The approval enhances the company's product pipeline in the cardiovascular disease treatment area, increasing its competitiveness in this field [1] Product Advantages - The product offers significant advantages over commonly used clinical medications, including faster onset of action, allowing for rapid, real-time, and precise blood pressure control [1] - It is particularly suitable for patients with liver and kidney dysfunction, as dosage adjustments are not required during treatment [1] - The product does not require dilution or preparation, which can significantly benefit patients at risk of fluid overload [1] Market Implications - The approval is expected to fill a clinical demand gap for emergency hypertension medications, thereby potentially increasing market share and revenue for the company in the cardiovascular sector [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2026年1月31日 | 狀態: | 新提交 | | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | 公司名稱: | 石藥集團有限公司 | | | | 呈交日期: | 2026年2月2日 | | | | I. 法定/註冊股本變動 不適用 | | | | FF301 第 1 頁 共 10 頁 v 1.2.0 FF301 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 1. 股份分類 普通股 股份類別 不適用 於香港聯交所上市 (註1) 是 證券代號 (如上市) 01093 說明 已發行股份（不包括庫存股份）數目 庫存股份數目 已發行股份總數 上月底結存 11,522,451,732 0 11,522,451,732 增加 / 減少 (-) 0 0 本月底結存 11,522,451,732 0 11,522,451,732 足夠公眾持股量的確認(註4) | 根據《主板上市規則》第13.32D(1)條或第19A.28D(1)條 / 《GEM上市規則》第 ...

Core Viewpoint - The approval of Chloride Dihydropyridine Injection by the National Medical Products Administration of China represents a significant advancement for the company in the treatment of hypertension, particularly for patients who cannot take oral medications [1] Group 1: Product Details - The product is a dihydropyridine calcium channel blocker, classified as a rapid-acting intravenous antihypertensive drug [1] - It is specifically designed for patients who are unsuitable for oral medication or have poor expected outcomes from oral treatments [1] Group 2: Advantages - The injection has notable advantages over commonly used clinical medications, including faster onset of action and the ability to achieve rapid, real-time, and precise blood pressure control [1] - It is particularly suitable for patients with liver and kidney dysfunction, as dosage adjustments are not required during treatment [1] - The product does not require dilution or preparation, which significantly benefits patients at risk of fluid overload [1] Group 3: Market Impact - The approval will enhance the company's product pipeline in the cardiovascular disease treatment sector, increasing its competitiveness in this field [1] - It is expected to address the clinical demand gap for emergency hypertension medications [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 （股份代號：1093） （於香港註冊成立之有限公司） 自願公告 氯維地平乳狀注射液獲藥品註冊批件 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）董 事 會（「 董 事 會 」）欣 然 宣 佈，本集團開發的氯維地平乳狀注射液(50ml: 25 mg、100ml: 50mg)（「該產品」）已獲得中華人 民共和國國家藥品監督管理局頒發的藥品註冊批件。 該產品是二氫吡啶類鈣通道阻滯拮抗劑，屬於速效靜脈降壓藥，適用於治療不適宜口服或 預期口服藥物治療效果不佳的高血壓患者。與臨床常用的治療藥物相比，該產品具有以下 顯 著 優 勢 ： 起 效 更 快 ， 可 實 現 血 壓 的 快 速 、 實 時 、 精 準 調 控 ； 更 適 用 於 肝 腎 功 能 異 常 患 者 ， 其 用 藥 期 間 無 需 調 整 劑 量 ； 使 用 時 無 需 稀 釋 配 製 ...

Core Insights - On February 2, 2026, Alibaba-W (09988), Tencent Holdings (00700), and China Mobile (00941) were the top three companies by trading volume in the Southbound Stock Connect, with transaction amounts of 6.121 billion, 4.166 billion, and 3.225 billion respectively [1] - In the Shenzhen-Hong Kong Stock Connect, Alibaba-W (09988), Tencent Holdings (00700), and SMIC (00981) also led the trading volume, with transaction amounts of 3.730 billion, 2.511 billion, and 2.012 billion respectively [1] Southbound Stock Connect Top Active Companies - Alibaba-W (09988) had a trading amount of 6.121 billion with a net buy of -0.816 billion [2] - Tencent Holdings (00700) recorded a trading amount of 4.166 billion with a net buy of +0.880 billion [2] - China Mobile (00941) had a trading amount of 3.225 billion with a net buy of -0.134 billion [2] - SMIC (00981) had a trading amount of 2.965 billion with a net buy of -29.8693 million [2] - Other notable companies included Xiaomi Group-W (01810) with a trading amount of 2.096 billion and a net buy of +0.391 billion [2] Shenzhen-Hong Kong Stock Connect Top Active Companies - Alibaba-W (09988) had a trading amount of 3.730 billion with a net buy of +0.488 billion [2] - Tencent Holdings (00700) recorded a trading amount of 2.511 billion with a net buy of +0.424 billion [2] - SMIC (00981) had a trading amount of 2.012 billion with a net buy of -1.32 billion [2] - Other significant companies included China Mobile (00941) with a trading amount of 1.401 billion and a net buy of +0.0651447 billion [2]

Market Overview - Southbound funds traded approximately HKD 138.285 billion today, a significant increase of about HKD 21.8 billion compared to the previous day, accounting for 39.75% of the total turnover of the Hang Seng Index, which has been below 40% for several consecutive days [2] - Despite the Hong Kong stock market accelerating downward, southbound funds saw a net inflow of approximately HKD 1.907 billion, with the Shanghai-Hong Kong Stock Connect recording a net inflow of about HKD 2.738 billion, while the Shenzhen-Hong Kong Stock Connect experienced a net outflow of approximately HKD 0.83 billion [2] Individual Stock Performance - Tencent Holdings (0700.HK) saw a significant net buy of HKD 1.304 billion, while its stock price fell by 1.24% [2][3] - Xiaomi Group-W (01810.HK) had a net buy of HKD 0.278 billion, with a stock price decline of 1.24% [2][3] - Huahong Semiconductor (01347.HK) experienced a net outflow of HKD 0.615 billion and a sharp decline of 11.24% [2][4] - Zijin Mining (02899.HK) had a net outflow of HKD 0.464 billion, with a stock price drop of 5.58% [2][4] - CSPC Pharmaceutical Group (01093.HK) saw a net outflow of HKD 0.393 billion and a decline of 4.69% [2][4] - Alibaba-W (09988.HK) experienced a net outflow of HKD 0.329 billion, with a stock price decrease of 3.49% [2][4] - SMIC (00981.HK) had a net outflow of HKD 0.162 billion, with a decline of 4.24% [2][4] Trading Activity - In the top ten active stocks on the Hong Kong Stock Connect (Shanghai), Alibaba-W had a net outflow of HKD 0.816 billion, while Tencent Holdings had a net inflow of HKD 0.880 billion [5] - On the Shenzhen Stock Connect, Alibaba-W recorded a net inflow of HKD 0.488 billion, while Huahong Semiconductor had a significant net outflow of HKD 0.554 billion [5]

Summary of Key Points Core Viewpoint - The Hong Kong stock market experienced significant net inflows from northbound capital, with a total net buy of HKD 19.07 billion on February 2, 2023, indicating strong investor interest in certain stocks while others faced net sell-offs [1]. Group 1: Northbound Capital Activity - Northbound capital recorded a net buy of HKD 27.38 billion through the Shanghai Stock Connect and a net sell of HKD 8.3 billion through the Shenzhen Stock Connect [1]. - The most bought stocks included Tencent (00700), Xiaomi Group-W (01810), and China Life (02628) [1]. - The most sold stocks were Hua Hong Semiconductor (01347), Zijin Mining (02899), and CSPC Pharmaceutical Group (01093) [1]. Group 2: Individual Stock Performance - Alibaba-W (09988) had a net sell of HKD 3.28 billion, with plans to invest HKD 30 billion in a "Spring Festival Treat Plan" [6][7]. - Tencent (00700) saw a net buy of HKD 13.03 billion, boosted by the launch of its "Yuanbao" Spring Festival red envelope activity, which is expected to increase downloads and user engagement [4]. - China Life (02628) received a net buy of HKD 1.87 billion, supported by positive forecasts for its individual insurance sales [5]. - Hua Hong Semiconductor (01347) faced a net sell of HKD 6.15 billion, amid tightening order reviews from major chip manufacturers [6]. - Zijin Mining (02899) experienced a net sell of HKD 4.64 billion, as it announced plans to issue USD 1.5 billion zero-coupon convertible bonds for project financing [7].

该行指，石药集团于去年5月公布将有3项潜在对外授权交易，是次协议应为第二项落实的交易，而落实 时间较预期延迟。由于协议中的资产处于早期阶段，该行未有将相关收入纳入预测，仅将协议首付款计 入预测，并将2026年收入及净利润预测分别上调27.9%及107.2%。 报告指，石药集团与阿斯利康合作达成协议，开发创新长效多肽药物，协议总价值最高可达185亿美 元。根据协议，石药将获得12亿美元的首付款，并有资格获得最高35亿美元的潜在研发里程碑付款，以 及最高138亿美元的潜在销售里程碑付款。 美银证券发布研报称，将石药集团(01093)目标价由8.5港元上调至9.1港元，但重申"跑输大市"评级，因 认为集团现有产品组合面临销售压力，且研发管线短期贡献有限，大多数关键资产仍处于早期阶段。 ...

美银证券发表研报指，石药集团与阿斯利康合作达成协议，开发创新长效多肽药物，协议总价值最高可 达185亿美元。根据协议，石药将获得12亿美元的首付款，并有资格获得最高35亿美元的潜在研发里程 碑付款，以及最高138亿美元的潜在销售里程碑付款。 该行指，石药集团于去年5月公布将有3项潜在对外授权交易，是次协议应为第二项落实的交易，而落实 时间较预期延迟。由于协议中的资产处于早期阶段，该行未有将相关收入纳入预测，仅将协议首付款计 入预测，并将2026年收入及净利润预测分别上调27.9%及107.2%。因此，该行将目标价由8.5港元上调至 9.1港元，但重申"跑输大市"评级，认为集团现有产品组合面临销售压力，且研发管线短期贡献有限， 大多数关键资产仍处于早期阶段。 ...

该行认为siRNA进入肥胖维持市场，将对所有胜肽类方案构成真正威胁。siRNA药物切入减重及肌保市 场，或最终挤压肽基肥胖疗法。该行密切追踪Arrowhead和Wave siRNA资产进展后，认为肥胖维持领域 正日益拥挤。建议投资人关注未来siINHBE和siALK7靶点对减重维持市场的影响。 招商证券国际发布研报称，石药集团(01093)与阿斯利康(AZN.US)达成历史性交易公告，表示看好交 易，但需等待石药或阿斯利康披露更多长效GLP-1全球开发细节。重申"中性"评级，认为短期基本面仍 存隐忧。 该行表示，根据石药最新公告，与阿斯利康合作的关键临床候选药物为SYH2082，长效GLP-1R/GIPR双 激动剂，现已进入I期临床。该行对此长效GLP-1平台了解甚少。SYH2082刚在中国启动I期研究。需等 待管理阶层揭露其设计细节及潜在临床开发路径，方能进行价值量化评估。该行维持"中国创新药进入 全球管线"的长期正面判断，但建议投资者仔细审视BD公告前已被市场计入预期的资产估值因素，并对 双方合作进展进行深度量化评估。 ...